Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2006

View Archived Issues

Novel format of a TRAIL fusion protein presented at a recent meeting

Therapeutic benefits of p38 MAP kinase inhibition for MDS

Phase IIa study under way for MEM-1003 in bipolar disorder

Two phase III studies of alfimeprase complete enrollment

MAXY-G34 for chemotherapy-induced neutropenia studied in phase I

Repros updates progress of clinical trials

Clearance for phase II trial of TroVax in late-stage breast cancer

eligen technology delivers active recombinant human growth hormone in study

Pharmos and Vela revise acquisition agreement

MAP-0004 studied for acute migraine headaches in new phase II trial

AnorMED Board recommends shareholders reject hostile Genzyme offer

RIO trials show efficacy of rimonabant in diabetic and nondiabetic overweight/obese patients

SEPI-PCI trial compares the efficacy and safety of otamixaban with UFH in PCI interventions

Multiple-dose pharmacokinetics and pharmacodynamics of AZD-6140 reported in healthy subjects

Logical Therapeutics inlicenses novel NSAID

Santhera and Juvantia collaborate on fipamezole for Parkinson's dyskinesia

Zealand raises capital for R&D

Enrollment completed in several phase III studies of ferumoxytol

Coprimary endpoints not met in phase III trial of LidoPAIN

rhThrombin offers good efficacy, better immunogenicity than bovine thrombin

NDA for CIP-Tramadol ER accepted for review

Recent patents describe new compounds for diabetes and related disorders

European orphan drug status for Neuprex in meningococcal disease

Glumetza now available in U.S.

Advisory Committee recommends against approval of Genasense in CLL

Novel nebivolol metabolites for cardiovascular disorders disclosed in recent Mylan patents

Novel compounds claimed for treatment of inflammatory disorders in recent patents

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...